From: <u>Denis Patterson</u>
To: <u>Pharmacy Services</u>

Subject: Advocate for Ubrogepant (Ubrelvy)

Date: Thursday, December 10, 2020 10:23:43 AM

To whom it may concern-

I am writing a letter to advocate for access to Ubrogepant (Ubrelvy) to treat my migraine patients. This medication in my clinical practice has shown to be very effective for treating the second leading cause of disability world wide (migraine).

Furthermore, it is a great option for my patients who have side effects from triptans or cardiovascular risk patients who cannot be on a triptan.

Feel free to call me to further elaborate on my email (775) 351-7172.

I am going to do my best to log on to the Webex meeting on 12/20/2020 to further speak about my clinical experience and advocate for Ubrogepant.

Thanks-

Denis

Denis G. Patterson, DO
Board Certified Pain Medicine
Board Certified Physical Medicine and Rehabilitation
President
Nevada Advanced Pain Specialists
Board of Directors, Pacific Spine & Pain Society
T 775.284.8650 F 775.284.8654
patterson@nvadvancedpain.com
www.nvadvancedpain.com

5578 Longley Lane | Reno, NV 89511 2385 E. Prater Way #204 | Sparks, NV 89434

This communication, its recipients, content and any attachments may contain confidential and proprietary information. These are meant only for authorized used by intended recipients only. Any other use is prohibited and may be cause for legal action. If you are not the intended recipient of this communication, please delete it from all your systems and contact the sender.